EXACT Sciences Corp. (EXAS)
Exact Sciences is a cancer screening and diagnostics company. Co.'s primary screening product, the Cologuard® test, is a non-invasive stool-based DNA screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Co.'s portfolio of Oncotype tests include: Oncotype DX gene expression tests for breast, prostate and colon cancers; Oncotype DX AR-V7 Nucleus Detect® test, a liquid-based test for advanced stage prostate cancer; and Oncotype MAP™ Pan-Cancer Tissue test (oncomap test), a test delivering tumor profiling to aid therapy selection for patients with metastatic, refractory or recurrent cancer.
EXAS SEC Filing Email Alerts Service
| Company Name: |
EXACT Sciences Corp. |
| Website: |
www.exactsciences.com |
| Sector: |
Biotechnology |
| Number of ETFs Holding EXAS: |
53 |
| Total Market Value Held by ETFs: |
$1.50B |
| Total Market Capitalization: |
$11.59B |
| % of Market Cap. Held by ETFs: |
12.94% |
|
|
April 20, 2024 • 1:16 AM Eastern
Strong Buy (3.68 out of 4)
100th percentile
|
|
Free EXAS Email Alerts:
